Hillrom ordered to complete BardyDx transaction by Delaware court

The court found recent Medicare rate cuts for long-term cardiac wearables did not qualify as a material adverse event, siding with Bardy Diagnostics. However, the judge did not grant BardyDx compensatory damages.

By Ricky Zipp • July 12, 2021

Biden order takes aim at high cost of hearing aids, calls for OTC sales

The executive order issued Friday directs HHS to consider issuing proposed rules within 120 days for allowing hearing aids to be sold over the counter. 

By Samantha Liss • Updated July 12, 2021

Digital health funding in 2021 smashes last year's record with $14.7B

Coronavirus-spurred momentum in the sector has only accelerated, according to a new Rock Health report.

By Rebecca Pifer • July 7, 2021

Boston Scientific spends $295M to snap up rest of cardiac ablation maker Farapulse

The deal adds to the medtech's electrophysiology portfolio in an increasingly competitive space that includes Medtronic and Johnson & Johnson.

By Ricky Zipp • June 24, 2021

Pear secures $400M to scale up digital therapeutic business in SPAC deal

The developer of the first three FDA-authorized prescription digital therapeutics has ambitions to grow sales from a projected $4 million this year to $125 million in 2023.

By Nick Paul Taylor • June 23, 2021

Roundup: Medtronic's HVAD recall problems continue following patient injuries, deaths

One year after Medtronic pulled the heart pump off the market, there have been two Class I recalls following reports of patient injuries and deaths. Here is a collection of MedTech Dive's coverage of the HVAD saga.

Updated June 27, 2022

Humana acquires Onehome to pursue value-based home health strategy

The deal for Miramar, Florida-based Onehome follows the insurer's recent purchase of home health giant Kindred at Home for $5.7 billion.

By Rebecca Pifer • June 15, 2021

Health data giants Ciox, Datavant merge in $7B deal

Real-world health data company Datavant and health record IT firm Ciox Health say combining forces will result in the largest health data ecosystem in the U.S. The merger is supported by investors including J&J and LabCorp.

By Rebecca Pifer • June 10, 2021

Medtronic's HeartWare HVAD ending brings questions about $1B acquisition

Nearly five years after Medtronic's buy of HeartWare International, the medtech giant pulled the flagship product of the deal due to safety risks, ceding the market to rival Abbott.

By Ricky Zipp • June 8, 2021

Abiomed buys preCARDIA to bag breakthrough heart failure device

William Blair analysts had hopes the buy could help Abiomed move past "two years of commercial disruptions" to drive long-term growth.

By Nick Paul Taylor • June 2, 2021

Medtronic steps up robotics bet as its challenger to Intuitive starts clinical trial

The medtech giant seeks to double or triple sales in its 2023 fiscal year. However, analysts warned that near-term investments will pressure margins in the short term.

By Nick Paul Taylor • May 28, 2021

PerkinElmer inks $155M Immunodiagnostic buyout, continuing deal spree

The flurry of M&A means PerkinElmer has struck more deals, at a higher aggregate value, in the first six months of 2021 than in the years since it bought Euroimmun for $1.3 billion in 2017.

By Nick Paul Taylor • May 18, 2021

FTC asks Allergan Aesthetics, Soliton for additional information on proposed $550M buyout

The regulator's second request for documentary material, which comes three months after the proposed deal was announced, is part of a deeper probe than its standard review of M&A.

By Nick Paul Taylor • Updated Aug. 11, 2021

NeoGenomics inks $390M Inivata buyout to enter liquid biopsy space

William Blair analysts wrote that NeoGenomics got a good price by setting the buyout fee last year.

By Nick Paul Taylor • May 6, 2021

LabCorp inks $150M takeover of Myriad Genetics autoimmune testing unit

The diagnostics giant discussed its interest in M&A last week, outlining plans to use up to $2 billion in free cash flow to strengthen its businesses through acquisitions.

By Nick Paul Taylor • May 4, 2021

Illumina sues European Commission to block competition probe into Grail buyout

The EU probe is the latest glitch in the takeover bid, which was panned by Wall Street and also faces scrutiny from the FTC. Analysts have said Exact Sciences could benefit from delays.

By Nick Paul Taylor • April 30, 2021

Boston Scientific sees Q1 electives rebound, hints at further 2021 M&A

With two acquisitions already in 2021, CFO Daniel Brennan said, "We have the appetite, and we have the balance sheet in place to continue to" spend later this year.

By Ricky Zipp • April 28, 2021

Moody's predicts brisk pace of medtech M&A amid earnings optimism

A new report from the ratings agency echoes initial commentary by bellwethers J&J and Edwards, which released financials this week.

By Susan Kelly • April 22, 2021

Robotics startup Vicarious raises $425M, including from BD, to take on giants

Aiming for a 510(k) submission in 2023 and to grow sales to $1 billion by 2027, the firm with high-profile backers including Bill Gates will face competition from Intuitive, J&J and Medtronic.

By Nick Paul Taylor • April 16, 2021

Thermo Fisher to buy research contractor PPD for $17.4B

The deal comes months after a failed attempt by the company to acquire molecular diagnostics company Qiagen. 

By Kristin Jensen • April 15, 2021

Italy's DiaSorin buys Luminex in $1.8B deal for multiplex molecular testing assets

The takeover comes weeks after Roche agreed to pay $1.8 billion to buy GenMark Diagnostics for its multiplex testing capabilities. The two targets compete with BioFire and Quidel.

By Nick Paul Taylor • April 12, 2021

Hologic pens $795M Mobidiag buyout to expand in acute care testing

Wall Street analysts cheered the move, with Evercore ISI writing "it fills a major hole in the company's armament." The deal marks Hologic's fourth pick-up of 2021, including the $230 million takeover of Biotheranostics in January.

By Nick Paul Taylor • April 9, 2021

LumiraDx lands on Nasdaq via SPAC with aim to undercut Abbott on price

The COVID-19 test maker hopes to generate enough capital to pursue a point-of-care testing opportunity it values at $76 billion. It has a ways to go to deliver.

By Nick Paul Taylor • April 8, 2021

Invitae inks $200M Genosity buyout, lands $1.2B investment to expand genetic testing

The medical genetics company expects Genosity's capabilities to increase access to its cancer test and reduce turnaround time, while a sizable investment led by SoftBank will support growth initiatives.

By Nick Paul Taylor • April 6, 2021

Quest sells minority share of Q2 Solutions for $760M

IQVIA, which previously owned 60% of Q2 Solutions, will now become the sole owner of the clinical trials laboratory company. Quest and IQVIA established Q2 Solutions as a joint venture in 2015.

By Ricky Zipp • April 1, 2021